Panhandle Nuclear RX, LTD.

Panhandle Nuclear RX, LTD., an NRC-licensed nuclear pharmacy partnership based in Amarillo, Texas, supplies radiopharmaceuticals to the Department of Veterans Affairs as a prime contractor on sole-source and full-and-open purchase orders and indefinite delivery contracts, with no subcontract footprint.

Panhandle Nuclear RX operates exclusively as a prime on radiopharmaceutical procurement for diagnostic imaging and nuclear medicine procedures. The vendor holds no federal vehicle seats and competes through direct purchase orders and single-award IDCs with the VA. The company's entire federal footprint concentrates with a single customer: the Department of Veterans Affairs Veterans Integrated Service Network 17 (VISN 17) in Amarillo accounts for 21 awards worth $5.7 million in combined potential value, representing 87% of the vendor's recent award count and 96% of its combined potential value across 55 prime awards. A single additional award to Veterans Integrated Service Network 22 accounts for $98 thousand. The vendor's most recent work includes a $650 thousand firm fixed-price purchase order awarded May 1, 2026, by VISN 17 for radiopharmaceutical supplies running through April 30, 2028; a $178 thousand order from May 1, 2025; and a $254 thousand delivery order from January 4, 2023. All work flows through a single-award IDC valued at $615 thousand with VISN 17, which expired January 3, 2025, and successive purchase orders and delivery orders issued against its replacement. Market research documentation for the 2026 award established that Panhandle Nuclear RX is the only NRC-licensed nuclear pharmacy in the Amarillo area capable of meeting the VA's requirements; the extreme shelf-life constraints of radiopharmaceutical products necessitate geographic proximity for timely patient care, which anchors the vendor to sole-source competitive advantage in its local market.

Award activity has been sparse and episodic — one award in 2024, two in 2025, one in 2026 — with a combined obligated value of $3.3 million (55% of potential value) across the portfolio. One award with potential value of $650 thousand reaches ultimate completion inside the next twenty-four months and faces recompete. The vendor's product mix is narrowly specialized: 25 awards in pharmaceutical preparation manufacturing and 48 awards under PSC Drugs and Biologicals reflect sustained focus on radiopharmaceutical supply to a single regional VA network.